These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 37521035)

  • 21. Myocardial recovery following left ventricular assist device implantation.
    Bhattacharya P; Samson R; Apte N; Fu S
    Indian J Thorac Cardiovasc Surg; 2023 Jul; 39(Suppl 1):154-160. PubMed ID: 37525711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation.
    Milder TY; Stocker SL; Baysari MT; Day RO; Greenfield JR
    Intern Med J; 2024 Apr; 54(4):559-567. PubMed ID: 37548317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Population Pharmacokinetic Study to Compare a Novel Empagliflozin L-Proline Formulation with Its Conventional Formulation in Healthy Subjects.
    Jiang X; Yu KS; Nam DH; Oh J
    Pharmaceuticals (Basel); 2024 Apr; 17(4):. PubMed ID: 38675482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic Comparison Between a Fixed-Dose Combination of Empagliflozin L-Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects.
    Lee H; Chung JY; Yu KS; Park SJ; Lee S
    Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1156-1163. PubMed ID: 37489552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic comparisons between two formulations containing 100 mg of miglitol in healthy male Korean volunteers: a randomized, open-label, single-dose, two-period, two-sequence crossover bioequivalence study.
    Choi HG; Jeon JY; Im YJ; Kim Y; Jang H; Kang S; Kim KH; Chae SW; Lee SY; Kim MG
    Int J Clin Pharmacol Ther; 2014 Jan; 52(1):55-63. PubMed ID: 24290415
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic comparisons of two acetyl-L-carnitine formulations in healthy Korean volunteers.
    Baek SM; Zheng R; Seo EJ; Hwang DY; Kim BH
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):980-6. PubMed ID: 26396135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects
.
    Lee H; Yim SV; Kim BH; Lee S
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):95-101. PubMed ID: 27841153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects.
    Jiang X; Bae S; Yoon DY; Park SJ; Oh J; Cho JY; Yu KS
    Drug Des Devel Ther; 2023; 17():2137-2145. PubMed ID: 37521035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction.
    Santos-Gallego CG; Requena-Ibáñez JA; Picatoste B; Fardman B; Ishikawa K; Mazurek R; Pieper M; Sartori S; Rodriguez-Capitán J; Fuster V; Badimon JJ
    Circ Cardiovasc Imaging; 2023 Apr; 16(4):e015298. PubMed ID: 37042253
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh.
    Pathan MDF; Akter N; Selim S; Saifuddin M; Qureshi NK; Kamrul-Hasan ABM; Hannan MA; Ahmed MAU; Mustari M; Chakraborty AK
    Diabetes Metab Syndr Obes; 2022; 15():4011-4021. PubMed ID: 36578878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism.
    Santos-Gallego CG; Mayr M; Badimon J
    Circulation; 2022 Sep; 146(11):819-821. PubMed ID: 36095062
    [No Abstract]   [Full Text] [Related]  

  • 32. Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance.
    Moon JS; Kim NH; Na JO; Cho JH; Jeong IK; Lee SH; Mok JO; Kim NH; Chung DJ; Cho J; Lee DW; Lee SW; Won KC
    Diabetes Metab J; 2023 Jan; 47(1):82-91. PubMed ID: 35722684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs.
    Cho HJ; Woo MR; Cho JH; Kim Y; Choi HG
    Pharm Dev Technol; 2022 Mar; 27(3):331-340. PubMed ID: 35264063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial.
    Requena-Ibáñez JA; Santos-Gallego CG; Rodriguez-Cordero A; Vargas-Delgado AP; Badimón JJ
    Diabetes Metab Syndr; 2022 Feb; 16(2):102417. PubMed ID: 35121204
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea.
    Yang H; Choi E; Park E; Na E; Chung SY; Kim B; Han SY
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00910. PubMed ID: 35005849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
    Anker SD; Butler J; Filippatos G; Ferreira JP; Bocchi E; Böhm M; Brunner-La Rocca HP; Choi DJ; Chopra V; Chuquiure-Valenzuela E; Giannetti N; Gomez-Mesa JE; Janssens S; Januzzi JL; Gonzalez-Juanatey JR; Merkely B; Nicholls SJ; Perrone SV; Piña IL; Ponikowski P; Senni M; Sim D; Spinar J; Squire I; Taddei S; Tsutsui H; Verma S; Vinereanu D; Zhang J; Carson P; Lam CSP; Marx N; Zeller C; Sattar N; Jamal W; Schnaidt S; Schnee JM; Brueckmann M; Pocock SJ; Zannad F; Packer M;
    N Engl J Med; 2021 Oct; 385(16):1451-1461. PubMed ID: 34449189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and socioeconomic burden of diabetes mellitus in South Korean adults: a population-based study using administrative data.
    Oh SH; Ku H; Park KS
    BMC Public Health; 2021 Mar; 21(1):548. PubMed ID: 33743612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
    Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Garcia-Ropero A; Ishikawa K; Watanabe S; Picatoste B; Vargas-Delgado AP; Flores-Umanzor EJ; Sanz J; Fuster V; Badimon JJ
    JACC Cardiovasc Imaging; 2021 Feb; 14(2):393-407. PubMed ID: 33129742
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.